After-Hours Top Losers: AeroVironment, HEALTHSOUTH Corp., Navidea Biopharmaceuticals, Jamba, ImmunoCellular Therapeutics Ltd

Lakeway, NY -- (SBWIRE) -- 03/06/2013 -- ThePennyStockProfiler.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on the following stocks:-

AeroVironment, Inc. (NASDAQ:AVAV) plunged 23.93% to $16.50 in the pre-market trading hours. The Company reported third quarter EPS of $0.17 from $0.26 in the prior year period. Revenues were $47.1 million from $72.0 million a year ago. The consensus estimates were for EPS of $0.37 and revenues of $89.02 million. The Company expects to report full year 2013 EPS of $0.30 to $0.50, with revenues of $230 million to $250 million. The consensus estimates are for EPS of $1.45 and revenues of $353.15 million

Is AVAV a Still a Buy after the Solid momentum? Let’s Find out Here

HEALTHSOUTH Corp. (NYSE:HLS) went down 2.62% to $24.15 in the pre-market trading hours. So far this year, the stock is up over 17%. The 52-week range for the stock is $18.44 and $24.99. HealthSouth Corporation is an owner and operator of inpatient rehabilitation hospitals.

Is HLS a Strong Buying Opportunity After The Recent Slump? Find out Here

Navidea Biopharmaceuticals Inc. (NYSEAMEX: NAVB) declined 3.17% to $3.05 in the pre-market trading hours. The Company will report its financial results for the fourth quarter and full year 2012 on March 6, 2013 after market close. The announcement will be followed by a conference call with the investment community, on March 7, 2013, at 8:30 a.m. EST to provide a business update and discuss its financial and operational results.

Should NAVB Buy NAVB After The Recent Movement? Let’s Find out Here

Jamba, Inc. (NASDAQ:JMBA) went down 5.59% to $2.70 in the pre-market trading hours. The company announced fourth quarter results. The net loss was $(6.9) million compared to net loss of $(9.8) million in the prior year period. System-wide comparable store sales increased 0.6% for the quarter compared to the prior year period. Total revenue for the fourth quarter was essentially flat at $44.2 million compared to the $44.3 million in the prior year period. Jamba’s non-GAAP adjusted operating profit increased $0.2 million to $5.6 million from prior year period.

Is JMBA a Strong Buying Opportunity After The Recent Slump? Find out Here

ImmunoCellular Therapeutics Ltd (NYSEAMEX: IMUC) increased 0.71% to $2.82 in the pre-market trading hours. The Company released fourth quarter results. The Company reported net income of $484,000, or $0.01 per share compared to a net loss of $1,499,000, or $0.05 per basic and diluted share for the quarter ended December 31, 2011. The Company reported that cash used in operations during 2012 was $12.4 million compared to $6.4 million in 2011.

Get Latest News, Updates on IMUC Here

About ThePennyStockProfiler.com
ThePennyStockProfiler.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. ThePennyStockProfiler.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at http://www.ThePennyStockProfiler.com

Disclaimer
The assembled information disseminated by ThePennyStockProfiler.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. ThePennyStockProfiler.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.